Authors
Latest:
Dr. Sequist on the Importance of Broad Molecular Testing in Lung CancerLecia V. Sequist, MD, MPH, discusses the importance of implementing broad molecular testing in lung cancer.
Latest:
Dr. Sequist Discusses Combination Regimens in EGFR+ NSCLCLecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non-small cell lung cancer (NCSLC).
Latest:
Dr. Sequist on Pembrolizumab Monotherapy in Nonsquamous NSCLCLecia V. Sequist, MD, MPH, the Landry Family Associate Professor of Medicine at Harvard Medical School, and director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital, discusses the use of pembrolizumab (Keytruda) monotherapy versus the combination of pembrolizumab and chemotherapy in advanced nonsquamous non–small cell lung cancer (NSCLC).
Latest:
Dr. Krug on Intra-Pleural Administration of GL-ONC1 in Patients With Malignant Pleural EffusionLee M. Krug, MD, associate attending physician, Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses a phase I study examining intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion.
Latest:
Dr. Schwartzberg on Emerging Biomarkers in NSCLCLee S. Schwartzberg, MD, FACP, chief and professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, executive director, West Cancer Center, discusses several emerging biomarkers in non–small cell lung cancer (NSCLC).
Latest:
Future Directions in HR+ Breast Cancer ManagementLee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.
Latest:
Dr. Schwartzberg on the Use of Myriad Genomic Testing in Cancer CareLee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.
Latest:
Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung CancerLeena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).
Latest:
Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice SettingsFirst-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.
Latest:
Dr. Bergsagel on Treatment Options for Relapsed/Refractory MyelomaLeif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses treatment options for patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Neumayer Discusses the POWER PIINC TrialLeigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.
Latest:
Biomarker Research in Ovarian CancerLeigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.
Latest:
Dr. Emens on Immune-Related Adverse Events in Ovarian CancerLeisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.
Latest:
Dr Gordon on Managing Toxicities Associated With Liso-Cel in MCLLeo I. Gordon, MD, discusses toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.
Latest:
Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCLA panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
Latest:
Dr. Gomella on Novel Biomarker Research in Prostate CancerLeonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.
Latest:
Dr. Gomella on the Challenges of Optimizing PSA as a Biomarker in Prostate CancerLeonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.
Latest:
Dr. Saltz Discusses FOLFIRINOX in Colorectal CancerLeonard Saltz, MD, executive director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the option of FOLFIRINOX for the treatment of patients with metastatic colorectal cancer.
Latest:
Dr. Shunyakov on the Impact of Genomics on Personalized Therapy in OncologyLeonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses how genomics have impacted personalized therapy in oncology.
Latest:
Leonie de Best on Validation of EMC92/SKY92 Signature in MyelomaLeonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma.
Latest:
Dr. Horn on Updated IMpower133 Data in Small Cell Lung CancerLeora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.
